Sex Reassignment: Endocrinological Interventions in Adults with Gender Dysphoria

Chapter
Part of the Focus on Sexuality Research book series (FOSR)

Abstract

Transgender people may wish to transition to the other sex, usually to the fullest extent possible. Part of that transition is enabled by the administration of cross-sex hormones and part by surgical adaptation. The treatment of male-to-female transgender people consists of blocking androgen action and allowing estrogens to feminize the body. For virilization of female-to-male transgender people, androgens usually suffice. In adulthood, certain features of the sex hormone-induced body shape cannot be undone (such as the larger size of bones in males, the hip configuration in females). After about 2–3 years, the maximally attainable effects of cross-sex hormones have been reached. With competent endocrinological advice, cross-sex hormone treatment is usually uneventful. The estrogen ethinyl estradiol is to be avoided in view of the risks of venous thrombosis and cardiovascular disease. Androgen administration does not lead to an increase in cardiovascular disease. Hormone-dependent cancers have been observed in transgender people but not to an alarming degree. The relative rarity of transsexualism and the scattering of endocrine treatment over many centers is an impediment to build a solid body of knowledge with regard to efficacy and safety of cross-sex hormone treatment.

Keywords

Estrogen Osteoporosis Adenoma Progesterone Estradiol 

Notes

Acknowledgements

Financial support was received from Stichting Reproductieve Geneeskunde, Amsterdam, the Netherlands.

References

  1. Asscheman, H., Giltay, E. J., Megens, J. A., de Ronde, W. P., van Trotsenburg, M. A., & Gooren, L. J. (2011). A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 164(4), 635–642.PubMedCrossRefGoogle Scholar
  2. Asscheman, H., Gooren, L. J., & Eklund, P. L. (1989). Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism, 38(9), 869–873.PubMedCrossRefGoogle Scholar
  3. Baglietto, L., Severi, G., English, D. R., Krishnan, K., Hopper, J. L., McLean, C., et al. (2010). Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiological Biomarkers Prevention, 19(2), 492–502.CrossRefGoogle Scholar
  4. Ballantyne, K. N., Kayser, M., & Grootegoed, J. A. (2011). Sex and gender issues in competitive sports: Investigation of a historical case leads to a new viewpoint. British Journal of Sports Medicine, 46(8), 614–617.PubMedCrossRefGoogle Scholar
  5. Becerra Fernandez, A., De Luis Roman, D., & Piedrola Maroto, G. (1999). Morbilidad en pacientes transexuales con autotratamiento hormonal para cambiar de sexo. Medicine Clinic (Barcelona), 113, 481–483.Google Scholar
  6. Benjamin, H. (1966). The transsexual phenomenon. New York, NY: Julian Press.Google Scholar
  7. Bentvelsen, F. M., Brinkmann, A. O., van der Schoot, P., van der Linden, J. E., van der Kwast, T. H., Boersma, W. J., et al. (1995). Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. Molecular and Cellular Endocrinology, 113(2), 245–253.PubMedCrossRefGoogle Scholar
  8. Bentz, E. K., Pils, D., Bilban, M., Kaufmann, U., Hefler, L. A., Reinthaller, A., et al. (2010). Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. Fertility and Sterility, 94(7), 2688–2696.PubMedCrossRefGoogle Scholar
  9. Bunck, M. C., Debono, M., Giltay, E. J., Verheijen, A. T., Diamant, M., & Gooren, L. J. (2009). Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Reports. pii: bcr02.2009.1589.Google Scholar
  10. Burcombe, R. J., Makris, A., Pittam, M., & Finer, N. (2003). Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast, 12(4), 290–293.PubMedCrossRefGoogle Scholar
  11. Cebula, H., Pham, T. Q., Boyer, P., & Froelich, S. (2010). Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochirurgica, 152(11), 1955–1956.PubMedCrossRefGoogle Scholar
  12. Choong, K., Lakshman, K. M., & Bhasin, S. (2008). The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian Journal of Andrology, 10(3), 351–363.PubMedCrossRefGoogle Scholar
  13. De Sutter, P. (2001). Gender reassignment and assisted reproduction: Present and future reproductive options for transsexual people. Human Reproduction, 16(4), 612–614.PubMedCrossRefGoogle Scholar
  14. Deipolyi, A. R., Han, S. J., & Parsa, A. T. (2010). Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. Journal of Clinical Neuroscience, 17(10), 1324–1326.PubMedCrossRefGoogle Scholar
  15. Dhand, A., & Dhaliwal, G. (2010). Examining patient conceptions: A case of metastatic breast cancer in an African American male to female transgender patient. Journal of General Internal Medicine, 25(2), 158–161.PubMedCrossRefGoogle Scholar
  16. Dhejne, C., Lichtenstein, P., Boman, M., Johansson, A. L., Langstrom, N., & Landen, M. (2011). Long-term follow-up of transsexual persons undergoing sex reassignment surgery: Cohort study in Sweden. PLoS One, 6(2), e16885.PubMedCrossRefGoogle Scholar
  17. Dimitrakakis, C., & Bondy, C. (2009). Androgens and the breast. Breast Cancer Research, 11(5), 212.PubMedCrossRefGoogle Scholar
  18. Dizon, D. S., Tejada-Berges, T., Koelliker, S., Steinhoff, M., & Granai, C. O. (2006). Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecologic and Obstetric Investigation, 62(4), 226–228.PubMedCrossRefGoogle Scholar
  19. Dorff, T. B., Shazer, R. L., Nepomuceno, E. M., & Tucker, S. J. (2007). Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clinical Genitourinary Cancer, 5(5), 344–346.PubMedCrossRefGoogle Scholar
  20. Dougherty, S. M., Mazhawidza, W., Bohn, A. R., Robinson, K. A., Mattingly, K. A., Blankenship, K. A., et al. (2006). Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocrine-Related Cancer, 13(1), 113–134.PubMedCrossRefGoogle Scholar
  21. Driak, D., & Samudovsky, M. (2004). Cervical cancer in a female-to-male trans-sexual. European Journal of Cancer, 40(11), 1795.PubMedCrossRefGoogle Scholar
  22. Galazis, N., Olaleye, O., Haoula, Z., Layfield, R., & Atiomo, W. (2012). Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: A systematic review and biomarker database integration. Fertility and Sterility, 98(6), 1590–1601.PubMedCrossRefGoogle Scholar
  23. Ganly, I., & Taylor, E. W. (1995). Breast cancer in a trans-sexual man receiving hormone replacement therapy. The British Journal of Surgery, 82(3), 341.PubMedCrossRefGoogle Scholar
  24. Garcia-Malpartida, K., Martin-Gorgojo, A., Rocha, M., Gomez-Balaguer, M., & Hernandez-Mijares, A. (2010). Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertility and Sterility, 94(3), 1097. e1013–e1095.PubMedCrossRefGoogle Scholar
  25. Gazzeri, R., Galarza, M., & Gazzeri, G. (2007). Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. The New England Journal of Medicine, 357(23), 2411–2412.PubMedCrossRefGoogle Scholar
  26. Gooren, L. J. (2011). Clinical practice. Care of transsexual persons. The New England Journal of Medicine, 364(13), 1251–1257.PubMedCrossRefGoogle Scholar
  27. Gooren, L. J., Assies, J., Asscheman, H., de Slegte, R., & van Kessel, H. (1988). Estrogen-induced prolactinoma in a man. The Journal of Clinical Endocrinology and Metabolism, 66(2), 444–446.PubMedCrossRefGoogle Scholar
  28. Gooren, L. J., & Behre, H. M. (2008). Testosterone treatment of hypogonadal men participating in competitive sports. Andrologia, 40(3), 195–199.PubMedCrossRefGoogle Scholar
  29. Gooren, L. J., & Bunck, M. C. (2004). Transsexuals and competitive sports. European Journal of Endocrinology, 151(4), 425–429.PubMedCrossRefGoogle Scholar
  30. Gooren, L. J., & Giltay, E. J. (2008). Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. The Journal of Sexual Medicine, 5(4), 765–776.PubMedCrossRefGoogle Scholar
  31. Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008). Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. The Journal of Clinical Endocrinology and Metabolism, 93(1), 19–25.PubMedCrossRefGoogle Scholar
  32. Gooren, L. J., Sungkaew, T., & Giltay, E. J. (2012). Exploration of functional health, mental well-being and cross-sex hormone use in a sample of Thai male-to-female transgendered persons (kathoeys). Asian Journal of Andrology. doi: 10.1038/aja.2012.139.Google Scholar
  33. Grabellus, F., Worm, K., Willruth, A., Schmitz, K. J., Otterbach, F., Baba, H. A., et al. (2005). ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast, 14(1), 71–74.PubMedCrossRefGoogle Scholar
  34. Grady, D., & Barrett-Connor, E. (2007). Postmenopausal hormone therapy. BMJ, 334(7599), 860–861.PubMedCrossRefGoogle Scholar
  35. Grynberg, M., Fanchin, R., Dubost, G., Colau, J. C., Bremont-Weil, C., Frydman, R., et al. (2010). Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reproductive Biomedicine Online, 20(4), 553–558.PubMedCrossRefGoogle Scholar
  36. Hage, J. J., Dekker, J. J., Karim, R. B., Verheijen, R. H., & Bloemena, E. (2000). Ovarian cancer in female-to-male transsexuals: Report of two cases. Gynecologic Oncology, 76(3), 413–415.PubMedCrossRefGoogle Scholar
  37. Hamburger, C. (1969). Endocrine treatment of male and female transsexualism (pp. 291–307). Baltimore, MD: Johns Hopkins Press.Google Scholar
  38. Handelsman, D. J., & Gooren, L. J. (2008). Hormones and sport: Physiology, pharmacology and forensic science. Asian Journal of Andrology, 10(3), 348–350.PubMedCrossRefGoogle Scholar
  39. Handelsman, D. J., & Heather, A. (2008). Androgen abuse in sports. Asian Journal of Andrology, 10(3), 403–415.PubMedCrossRefGoogle Scholar
  40. Haring, R., Volzke, H., Felix, S. B., Schipf, S., Dorr, M., Rosskopf, D., et al. (2009). Prediction of metabolic syndrome by low serum testosterone levels in men: Results from the study of health in Pomerania. Diabetes, 58(9), 2027–2031.PubMedCrossRefGoogle Scholar
  41. Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., III, Spack, N. P., et al. (2009). Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 94(9), 3132–3154.PubMedCrossRefGoogle Scholar
  42. Institute of Medicine (Ed.). (2011). The health of lesbian, gay, bisexual, and transgender people: Building a foundation for better understanding. Washington, DC: The National Academies Press.Google Scholar
  43. Ito, K. (2007). Hormone replacement therapy and cancers: The biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. The Tohoku Journal of Experimental Medicine, 212(1), 1–12.PubMedCrossRefGoogle Scholar
  44. Khosla, S. (2010). Update on estrogens and the skeleton. The Journal of Clinical Endocrinology and Metabolism, 95(8), 3569–3577.PubMedCrossRefGoogle Scholar
  45. Kovacs, K., Stefaneanu, L., Ezzat, S., & Smyth, H. S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archives of Pathology and Laboratory Medicine, 118(5), 562–565.PubMedGoogle Scholar
  46. Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012). Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews (Online), 7, CD004143.Google Scholar
  47. Mauras, N., Hayes, V., Welch, S., Rini, A., Helgeson, K., Dokler, M., et al. (1998). Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. The Journal of Clinical Endocrinology and Metabolism, 83(6), 1886–1892.PubMedCrossRefGoogle Scholar
  48. Meyer, W. J., Walker, P. A., & Suplee, Z. R. (1981). A survey of transsexual hormonal treatment in twenty gender-treatment centers. Journal of Sex Research, 17(4), 344–349.CrossRefGoogle Scholar
  49. Migeon, C. J., Rivarola, M. A., & Forest, M. G. (1968). Studies of androgens in transsexual subjects. Effects of estrogen therapy. The Johns Hopkins Medical Journal, 123(3), 128–133.PubMedGoogle Scholar
  50. Miksad, R. A., Bubley, G., Church, P., Sanda, M., Rofsky, N., Kaplan, I., et al. (2006). Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA: The Journal of the American Medical Association, 296(19), 2316–2317.CrossRefGoogle Scholar
  51. Molokwu, C. N., Appelbaum, J. S., & Miksad, R. A. (2008). Detection of prostate cancer following gender reassignment. BJU International, 101(2), 259. author reply 259–260.PubMedCrossRefGoogle Scholar
  52. Money, J. (1971). Transexualism and the philosophy of healing. The Journal of the American Society of Psychosomatic Dentistry and Medicine, 18, 25–26.Google Scholar
  53. Mueller, A., Dittrich, R., Binder, H., Kuehnel, W., Maltaris, T., Hoffmann, I., et al. (2005). High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. European Journal of Endocrinology, 153(1), 107–113.PubMedCrossRefGoogle Scholar
  54. Mueller, A., & Gooren, L. (2008). Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 159(3), 197–202.PubMedCrossRefGoogle Scholar
  55. Ott, J., Kaufmann, U., Bentz, E. K., Huber, J. C., & Tempfer, C. B. (2010). Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility and Sterility, 93(4), 1267–1272.PubMedCrossRefGoogle Scholar
  56. Pache, T. D., & Fauser, B. C. (1993). Polycystic ovaries in female-to-male transsexuals. Clinical Endocrinology, 39(6), 702–703.PubMedGoogle Scholar
  57. Pritchard, T. J., Pankowsky, D. A., Crowe, J. P., & Abdul-Karim, F. W. (1988). Breast cancer in a male-to-female transsexual. A case report. JAMA: The Journal of the American Medical Association, 259(15), 2278–2280.CrossRefGoogle Scholar
  58. Ruetsche, A. G., Kneubuehl, R., Birkhaeuser, M. H., & Lippuner, K. (2005). Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: A cross-sectional study. Osteoporosis International, 16(7), 791–798.PubMedCrossRefGoogle Scholar
  59. Schenck, T. L., Holzbach, T., Zantl, N., Schuhmacher, C., Vogel, M., Seidl, S., et al. (2010). Vaginal carcinoma in a female-to-male transsexual. The Journal of Sexual Medicine, 7(8), 2899–2902.PubMedCrossRefGoogle Scholar
  60. Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F., & Jacobs, P. A. (2008). Cancer incidence in women with Turner syndrome in Great Britain: A national cohort study. The Lancet Oncology, 9(3), 239–246.PubMedCrossRefGoogle Scholar
  61. Serri, O., Noiseux, D., Robert, F., & Hardy, J. (1996). Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. The Journal of Clinical Endocrinology and Metabolism, 81(9), 3177–3179.PubMedCrossRefGoogle Scholar
  62. Shao, T., Grossbard, M. L., & Klein, P. (2011). Breast cancer in female-to-male transsexuals: Two cases with a review of physiology and management. Clinical Breast Cancer, 11(6), 417–419.PubMedCrossRefGoogle Scholar
  63. Slagter, M. H., Gooren, L. J., Scorilas, A., Petraki, C. D., & Diamandis, E. P. (2006). Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. The Journal of Histochemistry and Cytochemistry, 54(8), 905–910.PubMedCrossRefGoogle Scholar
  64. Slattery, M. L., Sweeney, C., Murtaugh, M., Ma, K. N., Caan, B. J., Potter, J. D., et al. (2006). Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. International Journal of Cancer, 118(12), 3140–3146.CrossRefGoogle Scholar
  65. Storer, T. W., Magliano, L., Woodhouse, L., Lee, M. L., Dzekov, C., Dzekov, J., et al. (2003). Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. The Journal of Clinical Endocrinology and Metabolism, 88(4), 1478–1485.PubMedCrossRefGoogle Scholar
  66. Symmers, W. S. (1968). Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. British Medical Journal, 2(5597), 83–85.PubMedCrossRefGoogle Scholar
  67. Thurston, A. V. (1994). Carcinoma of the prostate in a transsexual. British Journal of Urology, 73(2), 217.PubMedCrossRefGoogle Scholar
  68. Toorians, A. W., Thomassen, M. C., Zweegman, S., Magdeleyns, E. J., Tans, G., Gooren, L. J., et al. (2003). Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. The Journal of Clinical Endocrinology and Metabolism, 88(12), 5723–5729.PubMedCrossRefGoogle Scholar
  69. T’Sjoen, G., Weyers, S., Taes, Y., Lapauw, B., Toye, K., Goemaere, S., et al. (2009). Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. Journal of Clinical Densitometry, 12(3), 306–313.PubMedCrossRefGoogle Scholar
  70. Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V. (2004). Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clinical Endocrinology, 61(5), 560–566.PubMedCrossRefGoogle Scholar
  71. Utian, W. H. (2012). A decade post WHI, menopausal hormone therapy comes full circle—Need for independent commission. Climacteric, 15(4), 320–325.PubMedCrossRefGoogle Scholar
  72. Van Caenegem, E., Wierckx, K., Taes, Y., Dedecker, D., Van de Peer, F., Toye, K., et al. (2012). Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. The Journal of Clinical Endocrinology and Metabolism, 97(7), 2503–2511.PubMedCrossRefGoogle Scholar
  73. van Haarst, E. P., Newling, D. W., Gooren, L. J., Asscheman, H., & Prenger, D. M. (1998). Metastatic prostatic carcinoma in a male-to-female transsexual. British Journal of Urology, 81(5), 776.PubMedCrossRefGoogle Scholar
  74. van Kesteren, P. J., Asscheman, H., Megens, J. A., & Gooren, L. J. (1997). Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology, 47(3), 337–342.PubMedCrossRefGoogle Scholar
  75. van Kesteren, P., Lips, P., Deville, W., Popp-Snijders, C., Asscheman, H., Megens, J., et al. (1996). The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. The Journal of Clinical Endocrinology and Metabolism, 81(6), 2227–2232.PubMedCrossRefGoogle Scholar
  76. van Kesteren, P., Lips, P., Gooren, L. J., Asscheman, H., & Megens, J. (1998). Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology, 48(3), 347–354.PubMedCrossRefGoogle Scholar
  77. Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., et al. (2012). Osteoporosis in men: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 97(6), 1802–1822.PubMedCrossRefGoogle Scholar
  78. Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., et al. (2012). Long-term evaluation of cross-sex hormone treatment in transsexual persons. The Journal of Sexual Medicine, 9(10), 2641–2651. doi: 10.1111/j.1743-6109.2012.02876.x.PubMedCrossRefGoogle Scholar
  79. Wierckx, K., Stuyver, I., Weyers, S., Hamada, A., Agarwal, A., De Sutter, P., et al. (2012). Sperm freezing in transsexual women. Archives of Sexual Behavior, 41(5), 1069–1071.PubMedCrossRefGoogle Scholar
  80. Wierckx, K., Van Caenegem, E., Pennings, G., Elaut, E., Dedecker, D., Van de Peer, F., et al. (2012). Reproductive wish in transsexual men. Human Reproduction, 27(2), 483–487.PubMedCrossRefGoogle Scholar
  81. Wigertz, A., Lonn, S., Mathiesen, T., Ahlbom, A., Hall, P., & Feychting, M. (2006). Risk of brain tumors associated with exposure to exogenous female sex hormones. American Journal of Epidemiology, 164(7), 629–636.PubMedCrossRefGoogle Scholar
  82. Yeap, B. B. (2009). Are declining testosterone levels a major risk factor for ill-health in aging men? International Journal of Impotence Research, 21(1), 24–36.PubMedCrossRefGoogle Scholar
  83. Yeap, B. B., Chubb, S. A., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., et al. (2009). Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: The health in men study. European Journal of Endocrinology, 161(4), 591–598.PubMedCrossRefGoogle Scholar
  84. Zitzmann, M., Erren, M., Kamischke, A., Simoni, M., & Nieschlag, E. (2005). Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. The Journal of Clinical Endocrinology and Metabolism, 90(12), 6603–6608.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.AndroconsultChiang MaiThailand
  2. 2.VU University Medical CenterAmsterdamThe Netherlands
  3. 3.HAJAPAmsterdamThe Netherlands

Personalised recommendations